P. 32-35 /

Who is making the pharmaceutical supply chain safe?

GUY VILLAX, MARIA JOSÉ MACEDO
Hovione
Sete Casas
Loures, 2674-506, Portugal

Abstract

Counterfeit medicines are anacknowledged crisis that takespatient risk to unacceptable levels – the authors argue thatthis is but the visible part of the iceberg. Counterfeit APIs arethe much larger submerged part of the iceberg. CounterfeitAPIs are a more serious issue as it represents a threat to theintegrity of the legal supply chain of medicines, it potentiallyimpacts a much larger number of patients and European andJapanese authorities do not yet perceive it as a threat – assuch they may well remain outside the scope of proposedfalsified medicines legislation and enforcement objectives. Thepharmaceutical industry and its supply chain appear alone attaking steps to address this criminal threat.


...